Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection
DL Braun, RD Kouyos, B Balmer… - Clinical Infectious …, 2015 - academic.oup.com
Background. Prospectively and systematically collected data on frequency and spectrum of
unexpected clinical manifestations during primary human immunodeficiency virus (HIV) …
unexpected clinical manifestations during primary human immunodeficiency virus (HIV) …
A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV Cohort …
DL Braun, B Hampel, B Ledergerber… - Clinical infectious …, 2021 - academic.oup.com
Background In 2016, the World Health Organization (WHO) introduced global targets for the
elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide HCV micro-…
elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide HCV micro-…
[HTML][HTML] Determinants of HIV-1 broadly neutralizing antibody induction
…, C Kadelka, H Ebner, M Schanz, M Huber, DL Braun… - Nature medicine, 2016 - nature.com
Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
Cohort profile update: the Swiss HIV cohort study (SHCS)
AU Scherrer, A Traytel, DL Braun… - International journal …, 2022 - academic.oup.com
The Swiss HIV Cohort Study (SHCS) provides a unique research platform for clinical,
translational, epidemiological, social and basic research. The SHCS was established in 1988. It is …
translational, epidemiological, social and basic research. The SHCS was established in 1988. It is …
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients
…, E Bernasconi, P Schmid, A Calmy, DL Braun… - Journal of …, 2017 - Elsevier
Background & Aims Hepatitis delta virus (HDV) infection accelerates the progression of hepatitis
B virus (HBV)-related liver disease. We assessed the epidemiological characteristics of …
B virus (HBV)-related liver disease. We assessed the epidemiological characteristics of …
[HTML][HTML] Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
…, R Katzensteiner, DL Braun… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic …
current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic …
[HTML][HTML] Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
…, C Berger, M Huber, J Böni, DL Braun… - Nature …, 2021 - nature.com
Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to
circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here …
circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here …
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
…, L Peters, D Elbirt, M Sarcletti, DL Braun… - The Lancet …, 2021 - thelancet.com
Background Weight gain effects of individual antiretroviral drugs are not fully understood.
We investigated associations between a prespecified clinically significant increase (>7%) in …
We investigated associations between a prespecified clinically significant increase (>7%) in …
Antibody response in immunocompromised patients after the administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine BNT162b2 or …
…, AL Eichenberger, B Hasse, DL Braun… - Clinical infectious …, 2022 - academic.oup.com
Background BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most
commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-…
commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-…
High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus …
DL Braun, B Hampel, R Kouyos… - Clinical infectious …, 2019 - academic.oup.com
Background This study was performed to investigate the efficacy and safety of grazoprevir-elbasvir
guided by baseline resistance-associated substitutions (RASs) in the Swiss HCVree …
guided by baseline resistance-associated substitutions (RASs) in the Swiss HCVree …
